SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks Therapeutics (Nasdaq: SWTX) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 12:30 p.m. ET in Coral Gables, Florida.
The event will be accessible via live webcast through the Events & Presentations page on SpringWorks' investor website. A replay will be available for a time after the conference. SpringWorks is a commercial-stage biopharmaceutical company specializing in severe rare diseases and cancer treatments.
SpringWorks Therapeutics (Nasdaq: SWTX) ha annunciato la sua partecipazione alla 7a Conferenza annuale Evercore ISI HealthCONx. La gestione dell'azienda parteciperà a una chiacchierata informale il martedì 3 dicembre 2024, alle 12:30 ET a Coral Gables, Florida.
L'evento sarà accessibile tramite webcast dal vivo attraverso la pagina Eventi e Presentazioni sul sito degli investitori di SpringWorks. Una registrazione sarà disponibile per un periodo dopo la conferenza. SpringWorks è un'azienda biofarmaceutica in fase commerciale specializzata in malattie rare gravi e trattamenti per il cancro.
SpringWorks Therapeutics (Nasdaq: SWTX) ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. La dirección de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a las 12:30 p.m. ET en Coral Gables, Florida.
El evento estará accesible a través de una transmisión en vivo en la página de Eventos y Presentaciones en el sitio web para inversores de SpringWorks. Una repetición estará disponible por un tiempo después de la conferencia. SpringWorks es una empresa biofarmacéutica en etapa comercial especializada en enfermedades raras severas y tratamientos contra el cáncer.
SpringWorks Therapeutics (Nasdaq: SWTX)는 제7회 연례 Evercore ISI HealthCONx 컨퍼런스에 참여할 것을 발표했습니다. 회사 경영진은 2024년 12월 3일 화요일 오후 12시 30분 ET에 플로리다주 코랄 게이블스에서 진행되는 대화에 참여할 예정입니다.
이 행사는 SpringWorks 투자자 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 실시간 웹캐스트로 접속할 수 있습니다. 행사 후 일정 기간 동안 다시 볼 수 있는 재생도 제공됩니다. SpringWorks는 중증 희귀 질환 및 암 치료를 전문으로 하는 상업 단계의 바이오 제약 회사입니다.
SpringWorks Therapeutics (Nasdaq: SWTX) a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx. La direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024, à 12h30 ET à Coral Gables, en Floride.
L'événement sera accessible par webcast en direct sur la page Événements et Présentations du site des investisseurs de SpringWorks. Une rediffusion sera disponible pendant un certain temps après la conférence. SpringWorks est une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares graves et les traitements du cancer.
SpringWorks Therapeutics (Nasdaq: SWTX) hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz angekündigt. Das Management des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 12:30 Uhr ET in Coral Gables, Florida, an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird über einen Live-Webcast auf der Seite Events & Präsentationen auf der Investorenwebsite von SpringWorks zugänglich sein. Eine Wiederholung wird für eine Zeit nach der Konferenz verfügbar sein. SpringWorks ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf schwere seltene Krankheiten und Krebsbehandlungen spezialisiert hat.
- None.
- None.
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET.
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Investors
investors@springworkstx.com
Media
media@springworkstx.com
FAQ
When is SpringWorks Therapeutics (SWTX) presenting at the Evercore ISI HealthCONx Conference 2024?
How can I watch SpringWorks Therapeutics' (SWTX) presentation at the 2024 HealthCONx Conference?
Will there be a replay available of SpringWorks Therapeutics' (SWTX) HealthCONx Conference presentation?
What type of presentation will SpringWorks Therapeutics (SWTX) give at the 2024 HealthCONx Conference?
